These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33182795)

  • 21. Formulation strategies for bacteriophages to target intracellular bacterial pathogens.
    Yan W; Banerjee P; Xu M; Mukhopadhyay S; Ip M; Carrigy NB; Lechuga-Ballesteros D; To KKW; Leung SSY
    Adv Drug Deliv Rev; 2021 Sep; 176():113864. PubMed ID: 34271022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phage therapy of wound-associated infections.
    Zyman A; Górski A; Międzybrodzki R
    Folia Microbiol (Praha); 2022 Apr; 67(2):193-201. PubMed ID: 35028881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant
    Racenis K; Rezevska D; Madelane M; Lavrinovics E; Djebara S; Petersons A; Kroica J
    Front Med (Lausanne); 2022; 9():851310. PubMed ID: 35547216
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viruses versus bacteria-novel approaches to phage therapy as a tool against multidrug-resistant pathogens.
    Viertel TM; Ritter K; Horz HP
    J Antimicrob Chemother; 2014 Sep; 69(9):2326-36. PubMed ID: 24872344
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance.
    Lin DM; Koskella B; Lin HC
    World J Gastrointest Pharmacol Ther; 2017 Aug; 8(3):162-173. PubMed ID: 28828194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of single and combined use of bacteriophages and antibiotics to inactivate Escherichia coli.
    Valério N; Oliveira C; Jesus V; Branco T; Pereira C; Moreirinha C; Almeida A
    Virus Res; 2017 Aug; 240():8-17. PubMed ID: 28746884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Lysis of Pathogenic Escherichia coli by Bacteriophages Releases Less Endotoxin Than by β-Lactams.
    Dufour N; Delattre R; Ricard JD; Debarbieux L
    Clin Infect Dis; 2017 Jun; 64(11):1582-1588. PubMed ID: 28329379
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phage Therapy in Bacterial Infections Treatment: One Hundred Years After the Discovery of Bacteriophages.
    Cisek AA; Dąbrowska I; Gregorczyk KP; Wyżewski Z
    Curr Microbiol; 2017 Feb; 74(2):277-283. PubMed ID: 27896482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Safety and Toxicity of Phage Therapy: A Review of Animal and Clinical Studies.
    Liu D; Van Belleghem JD; de Vries CR; Burgener E; Chen Q; Manasherob R; Aronson JR; Amanatullah DF; Tamma PD; Suh GA
    Viruses; 2021 Jun; 13(7):. PubMed ID: 34209836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phage therapy--constraints and possibilities.
    Nilsson AS
    Ups J Med Sci; 2014 May; 119(2):192-8. PubMed ID: 24678769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Systematic and Critical Review of Bacteriophage Therapy Against Multidrug-resistant ESKAPE Organisms in Humans.
    El Haddad L; Harb CP; Gebara MA; Stibich MA; Chemaly RF
    Clin Infect Dis; 2019 Jun; 69(1):167-178. PubMed ID: 30395179
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2005; 5(10):1-66. PubMed ID: 23074461
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of phage therapy via the intravenous route.
    Speck P; Smithyman A
    FEMS Microbiol Lett; 2016 Feb; 363(3):. PubMed ID: 26691737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacteriophages: A Therapy Concept against Multi-Drug-Resistant Bacteria.
    Rohde C; Wittmann J; Kutter E
    Surg Infect (Larchmt); 2018; 19(8):737-744. PubMed ID: 30256176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy.
    Ryan EM; Gorman SP; Donnelly RF; Gilmore BF
    J Pharm Pharmacol; 2011 Oct; 63(10):1253-64. PubMed ID: 21899540
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa.
    Wang J; Hu B; Xu M; Yan Q; Liu S; Zhu X; Sun Z; Reed E; Ding L; Gong J; Li QQ; Hu J
    Int J Mol Med; 2006 Feb; 17(2):309-17. PubMed ID: 16391831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical data and safety assessment of phage therapy in humans.
    Nale JY; Clokie MR
    Curr Opin Biotechnol; 2021 Apr; 68():310-317. PubMed ID: 33862490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Daptomycin in bone and joint infections: a review of the literature.
    Rice DA; Mendez-Vigo L
    Arch Orthop Trauma Surg; 2009 Nov; 129(11):1495-504. PubMed ID: 18989686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reapproaching Old Treatments: Considerations for PK/PD Studies on Phage Therapy for Bacterial Respiratory Infections.
    Schmalstig AA; Freidy S; Hanafin PO; Braunstein M; Rao GG
    Clin Pharmacol Ther; 2021 Jun; 109(6):1443-1456. PubMed ID: 33615463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How Good are Bacteriophages as an Alternative Therapy to Mitigate Biofilms of Nosocomial Infections.
    Singh A; Padmesh S; Dwivedi M; Kostova I
    Infect Drug Resist; 2022; 15():503-532. PubMed ID: 35210792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.